Navigation Links
OmniComm Systems, Inc. Is Fueled by Another Strong Quarter Delivering Electronic Data Capture (EDC) Solutions & Services

Q3 2008 Contracts Total $3,970,647, up 137% Over Q3 2007

FT. LAUDERDALE, Fla., Oct. 29 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture solutions for clinical trials, today announced another momentous quarter for new business. Signed contracts through the first 3 quarters of 2008, totaling $15.8M, are exceeding projected expectations for the year.

"It is not an accident that OmniComm continues to grow and prosper in these challenging economic times," said Stephen Johnson, COO of OmniComm. "We work hard to be in tune with our customers' needs and we are steadfast in our commitment to delivering an excellent product backed by even better customer service. We are flattered by the commitment that our customers have shown to us but we must not become complacent if we are going to live up to their expectations."

Thomas Wells, Vice President of Technology for OmniComm added, "Our customers are becoming EDC experts and expect much more than just the typical data collection and cleaning. Business intelligence and integration with external applications for better data handling have become necessities for our customers to meet the challenges of their expedited clinical timelines. OmniComm's vision for early 2009 includes the creation of a Centralized Data Hub where eClinical services can be seamlessly integrated with our clients' systems and repositories. This solution will empower our clients to take control of their data and better leverage core industry standards like CDISC and CDASH."

OmniComm continues to increase its customer base with a strong mix of new customer business coupled with steady, recurring business from its existing loyal customers. The following is a breakdown of new business for Q3, 2008.

Q3 New Contracts 2008:

Industry leading academic research center and best-in-class contract research organization choose OmniComm for Technology Transitions to bring TrialMaster in-house.


-- 5 month, Phase I, HIV study with 1 site and 44 subjects

-- 13 month, Phase IB, infectious disease study with 12 sites and 24


-- 4 month, Phase IV, HIV study with 30 sites and 160 subjects

-- 5 month, Phase I, infectious disease study with 1 site and 15 subjects

-- 24 month, Phase IV, hepatitis B study with 15 site and 30 subjects

-- 9 month, Phase I, infectious disease study with 1 site and 40 subjects

Contract Research Organizations

-- 30 month, Phase II, oncology study with 45 sites and 160 subjects

-- 24 month, Phase II oncology study with 8 site and subjects TBD

-- 6 month, Phase II, dermatology study with 25 sites and 200 subjects

-- 18 month, Phase II, cardiovascular study with 55 sites and 360 subjects

Medical Device

-- 15 month, study with 20 sites and 1000 subjects

-- 60 month, study with 28 sites and 225 patients


-- 18 month, Phase III, cardiovascular study with 10 sites and 60 subjects

-- 6 month, Phase I, oncology study with 25 sites and 172 patients

About OmniComm

OmniComm Systems, Inc. ( ) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small- to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Chicago, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm's future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm's operations, markets and profitability, actual results could differ materially and adversely from the expected results.

SOURCE OmniComm Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference
2. Avantis Medical Systems, Inc. Announces Key Leadership Appointments
3. CEOs Letter to Shareholders of Imaging Diagnostic Systems, Inc.
4. Concuity Announces Partnership with Financial Healthcare Systems, LLC
5. StemCor Systems, Inc. Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform
6. Solei Systems, Inc., Announces That the Company Is Now Publicly Traded
7. Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)
8. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
9. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
10. Cephalon Reports Another Strong Quarter
11. DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):